Accurate metabolite identification is critical in drug discovery, especially when differentiating oxidative metabolite isomers. Traditional methods often struggle to provide the resolution needed for confident structural elucidation. One of the challenges lies in distinguishing structurally similar metabolites, which can impact pharmacokinetics and safety assessments.
Hence a more precise approach is essential to streamline drug metabolism studies.
This app note highlights the advantages of electron-activated dissociation (EAD) in identifying oxidative metabolites of the molecular glue, mezigdomide. By leveraging EAD, researchers can gain deeper insights into unique fragmentation patterns, enabling more confident metabolite differentiation.
Download this application note to learn more about:
- How EAD improves structural elucidation of oxidative metabolite isomers
- A workflow that can be easily adapted to in vivo metabolism studies
- Cutting-edge technologies to accelerate the early drug discovery process
Differentiating Oxidative Metabolite Isomers of Mezigdomide Using Electron Activated Dissociation (EAD)
Mezigdomide, a molecular glue with potential therapeutic applications, undergoes oxidative metabolism, forming structurally similar isomers. Identifying these metabolite isomers is crucial for understanding their pharmacokinetics and biological impact. Advanced mass spectrometry techniques, such as Electron Activated Dissociation (EAD) and Collision-Induced Dissociation (CID), provide detailed fragmentation patterns that facilitate accurate differentiation of mezigdomide’s oxidative metabolites.
Key Highlights:
Mass Spectrometry Analysis: Utilization of EAD TOF MS/MS and CID TOF MS/MS to detect unique fragment ions of mezigdomide metabolites.
Structural Elucidation: Identifying critical mass-to-charge (m/z) ratios and fragmentation patterns to distinguish metabolite isomers.
Enhanced Sensitivity: Low mass error rates (ppm-level accuracy) improve the confidence in metabolite identification.
Applications in Drug Metabolism Studies: Supports drug development by providing insights into metabolic stability and potential bioactive metabolites.
Why Electron Activated Dissociation (EAD) Matters
EAD technology enhances drug metabolite identification by preserving labile bonds, enabling accurate structural analysis compared to conventional CID methods. This approach is particularly beneficial for compounds like mezigdomide, where metabolite isomers pose analytical challenges.
For detailed insights into this study and methodology, explore our resources on enhanced drug metabolite identification and automated metabolite analysis workflows.
